Silo Pharma's QwikAgents joins AMD AI developer program to accelerate AI agent platform

QwikAgents Gains Access to AMD Resources for AI Agent Platform Development

Silo Pharma announced that its wholly owned subsidiary QwikAgents has been accepted into the AMD AI developer program, a move designed to accelerate development of its next-generation AI agent platform 1

1

. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a developer community, supporting the continued development, testing, optimization, and benchmarking of the platform's artificial intelligence workloads .

Platform Targets Multiple User Segments with Scalable Pricing

QwikAgents is building an AI agent platform designed to provide dedicated, persistent configurable AI agents for individuals, developers, small businesses, and enterprises 1

1

. Users can deploy blank AI agents and, in the future, purpose-built agents for tasks including research, content generation, scheduling, coding, browser automation, and workflow automation . Starter plans are expected to begin at $14 per month, with infrastructure options that scale for more demanding workloads 1

1

.

Technical Architecture Emphasizes Reliability and Security

The platform is being designed to combine persistent memory, dedicated agent infrastructure, smart model routing, and encrypted backups with a simplified deployment process 1

1

. These features are intended to provide configurable AI agents across personal, developer, and business workflows 1

1

. Silo Pharma expects access to AMD's developer resources to help improve platform performance, increase agent reliability, and support the scalable deployment of autonomous AI agents capable of reasoning, executing tasks, and completing workflows with minimal human intervention 1

1

.

Market Response and Company Background

Silo Pharma stock experienced volatility following the announcement, with shares initially trading higher before pulling back and turning negative 1

1

. The stock closed at $5.28, down 6.7% over the past week, though analysis suggests the company appears undervalued at current levels . With a market capitalization of $5.73 million, the developmental-stage company maintains a strong current ratio of 9.65 and holds more cash than debt on its balance sheet .

Dual Focus on AI and Biopharmaceutical Pipeline

Beyond its AI initiative, Silo Pharma remains a developmental-stage biopharmaceutical company focused on therapies for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases 1

1

. Its biopharmaceutical pipeline includes SPC-15 for post-traumatic stress disorder, SP-26 for fibromyalgia and chronic pain, and a preclinical program targeting Alzheimer's disease 1

1

. Eric Weisblum, Chief Executive Officer of Silo Pharma, stated that "Joining the AMD AI Developer Program represents what we believe is an important step in advancing our QwikAgents platform" . The company previously joined the NVIDIA Developer Program, demonstrating its commitment to leveraging multiple AI ecosystems . Trading on Nasdaq, Silo Pharma recently regained compliance with the exchange's minimum closing bid price requirement .